JAIN MEHNDIRATTA & ASSOCIATES

Chartered Accountants

304, Crown Heights, Crown Plaza Hotel Complex, Sec. 10
Rohini, Delhi-110085
Tel No. 011-49847304, 9891064964, 9654941955
E-Mail: jma@cajain.co.in

INDEPENDENT AUDITOR'S REPORT

To

The Members of **Rebreathe Medical Devices Private Limited**

Report on the Standalone Financial Statements

1.Opinion

A. We have audited the accompanying financial statements of **M/s Rebreathe Medical Devices Private Limited** (The Company) which comprise the Balance Sheet as at 31st March 2026, the Statement of Profit & Loss for the year then ended, and a summary of significant accounting policies and other explanatory information. (Hereinafter referred to as "the financial statements").

B. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31st , 2026, its profit/loss for the year ended on that date.

2. Basis for Opinion

We conducted our audit of the financial statements in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

3. Information other than the financial statements and auditors' report thereon

A. The Company's board of directors is responsible for the preparation and presentation of the other information. The other information comprises the information included in the Board's Report including Annexures to Board's Report, but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

B. In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in this regard.

Jain Mehndiratta & Associates Chartered Accountants Delhi responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

III. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

IV. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

V. Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

VI. Assess and comment on company's compliance with implementation of Audit trail under Rule 3(1) of the Companies (Accounts) Rules, 2014.

VII. Evaluate that the company maintain back-up of the books of account and other relevant books and papers in electronic mode that should be accessible in India at all the times. Also, the Company create backup of accounts on servers physically located in India on a daily basis. This is as per the amended Rule 3 of the Companies (Accounts) Rules, 2014.

C. Materiality is the magnitude of misstatements in the Financial Statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We considered quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii)to evaluate the effect of any identified misstatements in the Financial Statements.

D. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

E. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

F. From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

II. Report on Other Legal and Regulatory Requirements

As required by the Companies (Auditor's report) Order, 2020 ("the Order") issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order.

1. As required by section 143(3) of the Act, we report that:

   A. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit;

Annexure A to the Auditors' Report

[Referred to in paragraph 1 under 'Report on Other Legal and Regulatory Requirements' of our Report of even date to the members of **Rebreathe Medical Devices Private Limited** on the accounts of the company for the year ended **31st March, 2026.**

In terms of the information and explanations sought by us and given by the company and the books of account and records examined by us in the normal course of audit and to the best of our knowledge and belief, we state that:

(i) In respect of the Company's Property, Plant and Equipment and Intangible Assets:

(a) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of the Property, Plant and Equipment.

(B) The Company has no intangible asset, therefore, this clause is not applicable to the company.

(b) As explained to us, Property, plant and equipment have been physically verified by the management during the year in accordance with the phased program of verification adopted by the management which, in our opinion, provides for physical verification of all the Property, plant and equipment.at reasonable intervals. According to the information and explanations given to us, no material discrepancies were noticed on such verification.

(c) According to the information and explanations given to us, all the immovable properties, which are coming in the books, are in the name of the company.

(d) The Company has not revalued any of its Property, Plant and Equipment and intangible assets during the year.

(e) No proceedings have been initiated during the year or are pending against the Company as at March 31, 2026 for holding any Benami property under the Benami Transactions (Prohibition) Act, 1988 (as amended in 2016) and rules made thereunder.

(ii) In respect of its inventory:

(a) As explained to us, the inventories of traded items were physically verified at regular intervals by the Management. In our opinion and according to the information and explanation given to us, the procedures of physical verification of inventories followed by the Management were reasonable and adequate in relation to the size of the Company and the nature of its business. The discrepancies noticed in physical verification of inventory as compared to books records were not 10% or more in aggregate of each class of inventory.

(b) The company has converted stock of Rs. 2.83 crores into Property, Plant and Equipment during F.Y 2025-26.

(iii) During the year the Company has not provided loans, advances in the nature of loans, stood guarantee or provided security to Companies, firms, Limited Liability Partnerships or any other

Jain Mehndiratta & Associates
Chartered Accountants
Delhi

financial institutions or any other lender during the year. Hence reporting under clause 3(ix) of the order is not applicable to the company.

(x) a) According to the information and explanations given to us and based on our examination of the records of the company, the Company has not raised moneys by way of initial public offer or further public offer (including debt instruments) during the year and hence reporting under this clause is not applicable.

b) According to the information and explanations given to us and based on our examination of the records of the company, during the year, the Company has not made any preferential allotment or private placement of shares or convertible debentures (fully or partly or optionally) during the year under audit and hence reporting under this clause is not applicable.

(xi) (a) No fraud by the Company and no material fraud on the Company has been noticed or reported during the year.

(b) No report under sub-section (12) of section 143 of the Companies Act has been filed in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government, during the year and up to the date of this report.

(c) According to the information and explanations given to us, during the year there are no whistle blower complaints received by the company during the year.

(xii) The Company is not a Nidhi Company as per the provisions of the Companies Act, 2013. Therefore, the requirement to report on clause 3(xii)(a), (b) and (c) of the Order is not applicable to the Company.

(xiii) In our opinion, and according to the information and the explanation given to us, all transactions with the related parties are in accordance with section 177 and 188 of the Companies Act, 2013, and the details of the same has been disclosed in the financial statements as required by the Indian accounting standards.

(xiv) (a) The Central Government has not prescribed to appoint internal auditor under section 138 of The Company Act 2013, for any of the services rendered by the company

(b) This clause is not applicable to the company.

(xv) In our opinion during the year the Company has not entered into any non-cash transactions with its Directors or persons connected with its directors and hence provisions of section 192 of the Companies Act, 2013 are not applicable to the Company.

(xvi) A. The provisions of section 45-IA of the Reserve Bank of India Act, 1934 (2 of 1934) are not applicable to the Company. Accordingly, the requirement to report on clause (xvi)(a) of the Order is not applicable to the Company.

B. The Company is not engaged in any Non-Banking Financial or Housing Finance activities. Accordingly, the requirement to report on clause (xvi)(b) of the Order is not applicable to the Company.

C. The Company is not a Core Investment Company as defined in the regulations made by Reserve Bank of India. Accordingly, the requirement to report on clause 3(xvi) of the Order is not applicable to the Company.

D. There are no other Companies part of the Group, hence, the requirement to report on clause 3(xvi)(d) of the Order is not applicable to the Company.

Jain Mahendratta & Associates Chartered Accountants Delhi

ANNEXURE B TO THE INDEPENDENT AUDITOR'S REPORT OF EVEN DATE ON THE FINANCIAL STATEMENTS OF REBREATHE MEDICAL DEVICES PRIVATE LIMITED

Report on the Internal Financial Controls under clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls with reference to financial statements of **Rebreathe Medical Devices Private Limited** ("the Company") as of March 31, 2026 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's Management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting Issued by the Institute of Chartered Accountants of India ("ICAI"). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, Including adherence to the Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditor's Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls with reference to these financial statements based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, as specified under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls, both issued by ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to these financial statements was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to these financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements included obtaining an understanding of internal financial controls with reference to these financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls with reference to these financial statements.

Meaning of Internal Financial Controls With Reference to these Financial Statements

A internal financial controls with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial controls with reference to financial statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Delhi

REBREATHE MEDICAL DEVICES PRIVATE LIMITED
CIN : U33119DL2021PTC383180
REG. ADD. : HOUSE -49, FLOOR 1ST , PKT-1, SEC 11, ROHINI, DELHI -110085
Period : 1st April 25 to 31st March, 2026

IT Computation

Particulars	**Amount (INR)**
Profit as per P&L	54,04,706
Add: Profit as per FMV diff a/c to Sec 28(vi)	6,46,009
Add: Depreciation as per Books	4,39,807
	64,90,522
Less: Depreciation as per I Tax	21,55,180
	43,35,342
Income Tax @22%	9,53,775
Add: Surcharge@10%	95,378
	10,49,153
Add: Eductaion Cess @4%	41,966
Net Tax Payable	**10,91,119**

Computation of Deffered Tax Asset / Liability

WDV of Assets as per Books		281,56,491
WDV of Assets as per I Tax Act		264,69,999
Difference of WDV		-16,86,492
Add: Profit as per FMV diff a/c to Sec 28(vi)		6,46,009
		-10,40,483
Tax on timing difference	DTL	**-2,61,786**
Provision as on 31/03/2025		7,270
Provision for Deferred Tax Asset(+)/Liability(-)		**-2,69,056**

REBREATHE MEDICAL DEVICES PRIVATE LIMITED
CIN : U33119DL2021PTC383180
REG. ADD. : HOUSE -49, FLOOR 1ST , PKT-1, SEC 11, ROHINI, DELHI -110085

STATEMENT OF STANDALONE FINANCIAL STATEMENT AS ON MARCH 31 2026

(₹ in Lakhs)

	Particulars	Notes	AS AT March 31, 2026	AS AT March 31, 2025
	ASSETS			
(1)	Non-Current Assets			
a)	Property, Plant and Equipment	3	281.56	0.48
b)	Capital Work in Progress			
c)	Investment Property			
d)	Goodwill			
e)	Other Intangible asset			
f)	Intangible assets under development			
g)	Biological assets other than bearer plants			
h)	Financial Assets			
	i) Investments	4	0.00	124.32
	ii) Trade Receivables			
	iii) Loans			
	iv) Other Financial Assets			
i)	Deferred Tax Assets (net)	5	0.00	0.07
j)	Other-Non Current Assets			
			281.56	124.87
(2)	Current Assets			
a)	Inventories	6	252.74	862.79
b)	Financial Assets			
	i) Investments			
	ii)Trade Receivables	7	1261.53	426.72
	iii)Cash and Cash Equivalents	8	4.53	6.27
	iv)Other Bank Balances	8A	104.84	
	v)Loans			
	vi)Other Financial Assets			
c)	Other Current Assets	9	317.79	75.59
			1941.43	1371.37
	TOTAL ASSETS		2223.00	1496.25
	EQUITY AND LIABILITIES			
(1)	Equity			
a)	Equity Share Capital	10	15.00	15.00
b)	Other Equity	11	275.49	235.04
			290.49	250.04
	Liabilities			
(2)	Non-Current Liabilities			
a)	Financial liabilities			
	i) Borrowings	12	1.18	1.18
	ii) Trade Payables			
	iii) lease liabilities			
	iv) Other Financial Liabilities			
b)	Provisions			
c)	Deferred Tax Liabilities (net)	5	2.62	
d)	Other Non-Current Liabilities			
			3.80	1.18

(3)	Current liabilities			
a)	Financial Liabilities			
	i) Borrowings			
	ii) Trade Payables	13		
	A. Total outstanding dues of micro enterprises and small enterprises			
	B. Total outstanding dues of creditors other than micro enterprises and small enterprises		1872.32	162.98
	iii) Other Financial Liabilities			
b)	Provisions	14	13.41	65.29
C)	Other Current Liabilities	15	42.99	1016.76
			1928.72	1245.03
	TOTAL EQUITY AND LIABILITIES		2223.00	1496.25
	Material Accounting Policies	1-2		

The accompanying notes form an integral part of the Financial Statements

As per our report of even date

For Jain Mehndiratta & Associates
[Chartered Accountants]
FRN: 018617N

Akshay Jain

[Partner]
M.No.: 543472
Place: Delhi
Date: 27/04/2026

Jain Mehndiratta & Associates Chartered Accountants Delhi

For Rebreathe Medical Devices India Private Limited

REBREATHE MEDICAL DEVICES INDIA PVT. LTD.

RAJESH RAI
(DIRECTOR)
DIN 09050751

ARUN HANDA
(DIRECTOR)
DIN 09226135

REBREATHE MEDICAL DEVICES PRIVATE LIMITED
CIN : U33119DL2021PTC383180
REG. ADD. : HOUSE -49, FLOOR 1ST , PKT-1, SEC 11, ROHINI, DELHI -110085

STATEMENT OF PROFIT & LOSS STATEMENT FOR THE YEAR ENDED 31ST MARCH 2026

(₹ in Lakhs)

	PARTICULARS	Note No.	For the Year ended March 31, 2026	For the Year ended March 31, 2025
I.	Revenue from operations	16	3,162.81	9,832.57
	Other income	17	8.56	8.65
	Total Revenue		3,171.38	9,841.22
II.	**Expenses**			
	Cost of materials consumed			
	Purchase of Goods	18	2,447.13	9,971.42
	Change in inventories of finished good, stock in trade and work in progress	19	610.05	(341.21)
	Employee benefits expense	20	39.83	59.97
	Finance costs	21	0.02	-
	Depreciation and amortisation expense	22	4.40	0.15
	Other expenses	23	15.91	14.19
	Total expenses		3,117.33	9,704.51
III.	Profit before exceptional and tax (I - II)		54.05	136.71
IV.	Exceptional items			
V.	Profit before tax (III-IV)		54.05	136.71
VI.	Tax expense:			
	(1) Current tax		10.91	34.41
	(2) Deferred tax		2.69	(0.01)
VII.	Profit/(loss) for the period from continued operations (v-vi)		40.45	102.29
IX.	Profit (Loss) for the period		**40.45**	**102.29**
X.	Other Comprehensive Income			
	(1) Items that will not be reclassified to profit or loss			
	(2)Income tax relating to items that will not be reclassifed to profit or loss			
XI.	Total Comprehensive Income for the period (IX+X)		40.45	102.29
	Paid up Equity Share capital (Face value of share of Rs 10/-)		1.50	1.50
	Earnings per equity share for continued operation.			
	(1) Basic		26.96	68.19
	(2) Diluted		26.96	68.19

Material Accounting Policies 1-2

The accompanying notes form an integral part of the Financial Statements

As per our report of even date

For Jain Mehndiratta & Associates
[Chartered Accountants]
FRN: 018617N

Akshay Jain
[Partner]
M.No.: 543472

Jain Mehndiratta & Associates Chartered Accountants Delhi

Place: Delhi
Date: 27/04/2026

For Rebreathe Medical Devices India Private Limited

REBREATHE MEDICAL DEVICES INDIA PVT. LTD.

RAJESH RAI
(DIRECTOR)
DIN 09050751

ARUN HANDA
(DIRECTOR)
DIN 09226135

REBREATHE MEDICAL DEVICES PRIVATE LIMITED

CIN : U33119DL2021PTC383180

REG. ADD. : HOUSE -49, FLOOR 1ST , PKT-1, SEC 11, ROHINI, DELHI -110085

CASH FLOW STATEMENT FOR THE YEAR ENDING 31 MARCH, 2026

	Particulars	Amt(Rs. lacs)		Amt(Rs. lacs)	
		2025-26		2024-25	
	CASH FLOW FROM OPERATIONS				
A)	Profit before taxation	54.05		136.71	
B)	**Adjustments**				
	Add:				
(i)	Depreciation and amortisation	4.40		0.15	
(ii)	Interest Expenses			-	
(iii)	Loss on sale of Machinery			-	
	Less:				
	Provision for taxation	-		-	
	Provision for Gratuity	-		-	
	Interest Income	8.56		8.33	
	Profit on Sale of Fixed assets	-		-	
	Operating profit before working capital changes		49.88		128.53
C)	**(Increase)/Decrease in current assets**				
(i)	Inventories	324.55		-341.21	
(ii)	Trade Receivables	-834.81		101.39	
(iii)	Loans & advances and other current assets	-		-	
(iv)	other current assets	-242.20		134.57	
	Increase/(Decrease) in current liabilities				
(i)	Trade Payables	1,709.34		-828.33	
(ii)	Other current liabilities	-973.77		806.19	
(iii)	Provisions	-62.79		-	
			-79.67		-127.39
	Cash generated from operations		**-29.79**		**1.14**
	Investing Activities				
(i)	Purchase of fixed assets	-		-	
(ii)	Sale of fixed assets	-		-	
(iii)	Other Non current Assets	19.48		-7.49	
(iv)	Interest Income	8.56		8.33	
	Net cash from investing activities		**28.04**		**0.84**
	Financing activities				
(i)	Long term borrowings	-		-	
	Share Capital issued	-		-	
	Short Term borrowings	-		-	
(ii)	Financial Cost	-		-	
	Net cash from Financing activities		-		-
	Net change in cash and cash equivalents		**-1.75**		**1.98**

Jain [illegible] & Associates
Chartered Accountants
Delhi

REBREATHE MEDICAL DEVICES INDIA PVT. LTD.

REBREATHE MEDICAL DEVICES INDIA PVT. LTD.

	Cash balance as on beginning	3.52		-	
	Bank balance as on beginning	2.76		3.52	
	Bank Overdraft as on Beginning	-		0.78	
	Cash balance as at end	3.52		3.52	
	Bank balance as at end	1.02		2.76	
	Bank Overdraft as at end (Debit Balance)	-		-	
	Net change in cash and cash equivalents		**-1.75**		**1.98**

Material Accounting Policies 1-2

The accompanying notes form an integral part of the Financial Statements

As per our report of even date

For Jain Mehndiratta & Associates
[Chartered Accountants]
FRN: 018617N

Akshay Jain
[Partner]
M.No.: 543472
Place: Delhi
Date: 27/04/2026

For Rebreathe Medical Devices India Private Limited

RAJESH RAI
(DIRECTOR)
DIN 09050751

ARUN HANDA
(DIRECTOR)
DIN 09226135

REBREATHE MEDICAL DEVICES PRIVATE LIMITED

(₹ in Lakhs)

Standalone Statement of changes in Equity

(1) Current reporting period

	Share application money pending allotment	Equity component of compound financial instruments	Reserve and Surplus										Money received against share warrants	Total
			Capital Reserve	Securities Premium	Other Reserves (specify nature)	Retained Earning s	Debt instruments through Other Comprehensive Income	Equity Instruments through Other Comprehensive Income	Effective portion of Cash Flow Hedges	Revaluati on Surplus	Exchange differences on translating the financial statements of a foreign operation	Other items of Other Comprehensive Income (specify nature)		
Balance at the beginning of the current reporting period						235.04							-	235.04
Changes in accounting policy or prior period error														-
Restated balance at the beginning of the current reporting period														-
Total Comprehensive Income for the current year						40 45								40.45
Dividends														
Other Adjustments														-
Balance at the end of the current reporting period	-	-	-	-	-	275.49	-	-	-	-	-	-	-	275.49

(2) Previous Reporting Period

	Share application money pending allotment	Equity component of compound financial instruments	Reserve and Surplus										Money received against share warrants	Total
			Capital Reserve	Securities Premium	Other Reserves (specify nature)	Retaine d Earning s	Debt instruments through Other Comprehensive Income	Equity Instruments through Other Comprehensive Income	Effective portion of Cash Flow Hedges	Revaluatio n Surp us	Exchange differences on translating the financial statements of a foreign operation	Other items of Other Comprehensive Income (specify nature)		
Balance at the beginning of the current reporting period						132 75								132.75
Changes in accounting policy or prior period error														
Restated balance at the beginning of the current reporting period														
Total Comprehensive Income for the current year						102 29								102.29
Dividends paid														
Other Adjustment														
Balance at the end of the current reporting period	-	-	-	-	-	235.04	-	-	-	-	-	-	-	235.04

1. Corporate Information

Rebreathe Medical Devices Private Limited (hereinafter referred to as "the Company") was incorporated on 05 December 2021as a private limited company under the Companies Act, 2013 and having its registered office at House No 49 Floor 1st Block-F Pkt 1 Sec 11 Landmark Near Metro Walk Rohini , Delhi, Delhi, India - 110085. The Company is a wholly owned subsidiary of Servotech Renewable Power Systems Limited (formally known as Servotech Power Systems Limited) ('the holding company'). The Company is engaged in the business of manufacturing and wholesale/retail trade of medical and surgical equipment and EV Chargers and related items.

2. Significant Accounting Policies

This note provides a list of the significant accounting policies adopted in the preparation of these financial statements. These policies have been consistently applied to all the years presented, unless otherwise stated.

(a) Basis of preparation and presentation

(i) Compliance with Ind AS

The financial statements comply in all material aspects with Indian Accounting Standards (Ind AS) notified under Section 133 of the Companies Act, 2013 (the Act) [read with relevant rules issued thereunder] and other relevant provisions of the Act.

(ii) Historical cost convention

The financial statements have been prepared on a historical cost basis except certain financial assets and liabilities that is measured at fair value.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, regardless of whether that price is directly observable or estimated using another valuation technique. In estimating the fair value of an asset or a liability, the Company takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date.

(iii) Use of Estimates

In the application of the Company's accounting policies, which are described in note 2, the directors of the Company are required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods.

(b) Revenue Recognition

Revenue from Contracts with Customers which establishes principles for revenue recognition that apply to all contracts with customers except those relating to financial instruments, leases and insurance contracts and requires an entity to recognize revenue as performance obligations are satisfied. Ind AS 115 specifies that variable consideration is only recognized when the related performance obligation has been satisfied and to the extent that it is highly probable that a significant reversal will not occur when the uncertainty associated with the variable consideration is subsequently resolved.

Delhi

(e) Provisions

Provisions are recognised when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that the Company will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation.

The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligation. When a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value of those cash flows (when the effect of the time value of money is material).

(f) Financial Assets

All recognised financial assets are subsequently measured in their entirety at either amortised cost or fair value, depending on the classification of the financial assets.

Classification of financial assets

Financial assets that meet the following conditions are subsequently measured at amortised cost (except for financial assets that are designated as at fair value through profit or loss on initial recognition):

- the asset is held within a business model whose objective is to hold assets in order to collect contractual cash flows; and
- the contractual terms of the instrument give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

Financial assets that meet the following conditions are subsequently measured at fair value through other comprehensive income (except for financial assets that are designated as at fair value through profit or loss on initial recognition):

- the asset is held within a business model whose objective is achieved both by collecting contractual cash flows and selling financial assets; and
- the contractual terms of the instrument give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

All other financial assets are subsequently measured at fair value.

Effective interest method

The effective interest method is a method of calculating the amortised cost of a financial asset and of allocating interest income over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset, or, where appropriate, a shorter period, to the net carrying amount on initial recognition.

Income is recognised on an effective interest basis for financial assets other than those financial assets classified as at fair value through profit or loss. Interest income is recognised in the Statement of profit and Loss.

Derecognition of financial assets

The Company derecognises a financial asset when the contractual rights to the cash flows from the asset expire, or when it transfers the financial asset and substantially all the risks and rewards of ownership of the asset to another party.

On derecognition of a financial asset in its entirety, the difference between the asset's carrying amount and the sum of the consideration received and receivable is recognised in the Statement of Profit and Loss.

Chartered Accountants
Delhi

All other assets are classified as non-current.

A liability is classified as current if:
(a) it is expected to be settled in normal operating cycle;
(b) it is held primarily for the purpose of trading;
(c) it is expected to be settled within twelve months after the reporting period;
(d) it has no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period.

All other liabilities are classified as non-current.

The operating cycle is the time between acquisition of assets for processing and their realization in cash and cash equivalents. The Group's normal operating cycle is twelve months.

(i) Leases

The Company's lease asset consists of leases for building for office premises. The Company assesses whether a contract contains a lease, at inception of a contract. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

The right-of-use assets are initially recognized at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or prior to the commencement date of the lease plus any initial direct costs less any lease incentives. They are subsequently measured at cost less accumulated depreciation and impairment losses.

The lease liability is initially measured at amortized cost at the present value of the future lease payments. The lease payments are discounted using the interest rate implicit in the lease or, if not readily determinable, using the incremental borrowing rates in the country of domicile of these leases.

Lease liability and right-of-use asset have been separately presented in the Balance Sheet and lease payments have been classified as financing cash flows.

(j) Cash Flow Statement

Cash flows are reported using the indirect method, where by profit before tax is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future operating cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the Company are segregated.

(k) Security Deposits

Under Ind AS, all financial assets are required to be recognised at fair value. Difference between the fair value and transaction value of the security deposit has been recognised as prepaid expenses is amortised over the period of security deposit on straight line basis. Notional interest income on such deposit is recognised over the security period using effective interest method.

2A. Recent pronouncements

Ministry of Corporate Affairs ("MCA") notifies new standard or amendments to the existing standards under Companies (Indian Accounting Standards) Rules as issued from time to time. On March 23, 2022, MCA amended the Companies (Indian Accounting Standards) Amendment Rules, 2022, applicable from April 1st, 2022, as below:

Ind AS 16 – Proceeds before intended use The amendments mainly prohibit an entity from deducting from the cost of property, plant and equipment amounts received from selling items produced while the Company is

Depreciation as per Companies Act 2013

"NOTE 3 'Property Plant and Equipments'

The Changes in the carrying value of Property Plant and equipments Including capital; work in progress

Particulars	Machinery	Computer and Printers	Furnitures and Fixtures	Total
Dep Rate %	**0.18**	**0.63**	**0.26**	-
Demmed Cost- 1 April. 2025	0.33	1.28	0.55	2.16
Additions	285.48		-	285.48
Disposals	-	-	-	-
As at 31st March 2026	285.81	1.28	0.55	287.64
Accumulated Depreciation				
Accumulated Dep 01 April, 2025	0.15	1.22	0.31	1.68
Depreciation as on 31st March 2026	4.35	-	0.05	4.40
Depreciation on Additions	-	-	-	-
Disposals	-	-	-	-
As at 31st March 2026	4.50	1.22	0.35	6.08
Net Bock as on 31st March 2026	281.30	0.06	0.20	281.56

Jain Mohindratta & Associates Chartered Accountants Delhi

REBREATHE MEDICAL DEVICES INDIA PVT. LTD.

REBREATHE MEDICAL DEVICES INDIA PVT. LTD.

REBREATHE MEDICAL DEVICES PRIVATE LIMITED
CIN : U33119DL2021PTC383180
REG. ADD. : HOUSE -49, FLOOR 1ST , PKT-1, SEC 11, ROHINI, DELHI -110085

Notes Forming Part of the Financial Statements

(₹ in Lakhs)

	Particulars	As at March 31, 2026	As at March 31, 2025
Note 4	**Investments**		
	FDR	-	124.32
	Total	**-**	**124.32**
Note 5	**Deferred tax**		
	DTA	-2.62	0.07
	Total	**-2.62**	**0.07**
Note 6	**Inventories**		
	(valued at lower of cost and net realisable value)		
	Finished Goods	-	165.21
	Raw Material	252.74	696.85
	Semi finished goods	-	0.74
	Total	**252.74**	**862.79**
	Note: The Company has converted Inventory of Rs. 2.83 Crore to Capital Asset during FY 2025-26		
Note 7	**Trade receivables**		
	Trade receivables	1,261.53	426.72
	(Ageing as per Annexure)		
	Total	**1,261.53**	**426.72**
Note 8	**Cash and cash equivalents**		
	Bank	1.02	2.75
	Cash in hand	3.52	3.52
		4.53	6.27
Note 8A	Other Bank Balances		
	~Balance in FDR	104.84	-
	Total	**109.38**	**6.27**
Note 9	**Other Current Assets**		
	Accrued Interest on FDR	24.03	-
	Advance Tax	9.63	41.91
	Advance to Employee	0.34	0.34
	Advance to Supplier	258.22	4.90
	GST Receivable	21.98	22.88
	Security Deposits	0.87	0.87
	TCS Receivable	-	1.96
	TDS Receivable	2.72	2.73
		317.79	**75.59**

Jain Mahendra & Associates Chartered Accountants Delhi

REBREATHE MEDICAL DEVICES INDIA PVT. LTD.

REBREATHE MEDICAL DEVICES INDIA PVT. LTD.

(₹ in Lakhs)

Note 10	Share Capital Particulars	As at March 31, 2026	As at March 31, 2025
	The authorized, issued, subscribed and fully paid up share capital comprises of equity shares having a par value of Rs. 10/- each		
	Authorised Capital		
	150000 Equity Shares of Rs. 10/- each	15.00	15.00
		15.00	**15.00**
	Issued, Subscribed & Paid up capital		
	to the subscribers of the Memorandum		
	150000 Equity Shares of Rs. 10/- each	15.00	15.00
		15.00	**15.00**

Note 10(A) Details of Shares Holding more than 5% shares in the Company

Particulars	% Holding	No. of Shares
Equity Shares of Rs. 10 each fully paid up		
Servotech Renewable Power System Limited	0.95	142500
	0.95	**142500**

Note 10(B) Shares held by Promotors

Current Reporting Period

S.No.	Promotor's Name	No. of Shares	% of Total Shares
1	Servotech Renewable Power System Limited	142500	95.00%
2	Raman Bhatia	3000	2.00%
3	Sarika Bhatia	3000	2.00%
4	Arun Handa	1500	1.00%

Previous Reporting Period

S.No.	Promotor's Name	No. of Shares	% of Total Shares
1	Servotech Renewable Power System Limited	142500	95.00%
2	Raman Bhatia	3000	2.00%
3	Sarika Bhatia	3000	2.00%
4	Arun Handa	1500	1.00%

Note-10(C) **Statements of Change in Equity**

(1) Current Reporting Period

Balance at the beginning of the current reporting period	Changes in Equity share capital due to prior period errors	Restated balance at the beginning of the current reporting period	Changes in equity shre capital during th current year	Balance at the end of the current reporting period
142500				142500
3000				3000
3000				3000
1500				1500
150000				**150000**

(2) Previous Reporting Period

Balance at the beginning of the current reporting period	Changes in Equity share capital due to prior period errors	Restated balance at the beginning of the current reporting period	Changes in equity shre capital during th current year	Balance at the end of the current reporting period
142500				142500
3000				3000
3000				3000
1500				1500
150000				**150000**

Note-10(D) **Terms, rights & preferences attached to equity shares**

Each Holder of Equity Shares are entitled to one vote per share. In the event of Liquidation of the company, the holders of equity shares will be entitled to receive remaining assets of the company , after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders. There is no restriction on distribution of dividend . However, same is subject to the approval of shareholders in the AGM.

Note-10(E) **The Company has not issued any bonus shares or shares for consideration other than cash since its commencement**

(₹ in Lakhs)

Note 11 **Other Equity**

Particulars	As at March 31, 2026	As at March 31, 2025
Surplus in statement of Profit & Loss		
Opening Balance	235.04	132.75
Add: Net Profit for the current Year	40.45	102.29
Add: Other Depreciation Adjustments	-	-
Closing Balance	**275.49**	**235.04**

Financial Liabilities

Note-12 **Non-Current Borrowings**

Particulars		
Secured from banks		
i) From Bank	-	-
ii) From Non Banking Companies	-	-
Unsecured Loans		
i) From Bank	-	-
ii) From Non Banking Companies	-	-
iii) From Directors	1.18	1.18
Total Non current borrowings	**1.18**	**1.18**

Jain Manoj & Associates Chartered Accountants Delhi

REBREATHE MEDICAL DEVICES INDIA PVT. LTD.

REBREATHE MEDICAL DEVICES INDIA PVT. LTD.

		As at March 31, 2026	As at March 31, 2025
Note-13	**Trade Payables**		
	Sundry Creditors	1,872.32	162.98
	(Ageing as per Annexure)	**1,872.32**	**162.98**
Note-14	**Short term Provisions**		
	Provision for Audit Fees	1.00	1.00
	Provision for Income Tax	10.91	64.29
	Provision for Expenses	1.50	-
		13.41	**65.29**
Note-15	**Other Current Liabilities**		
	Advance From Customer	-	1,012.63
	Employee contractual welfare	0.32	0.29
	Employer contractual welfare	0.32	-
	Salary payable	3.16	2.97
	TDS & TCS Payable	0.92	0.63
	GST Payable	2.15	-
	GR/IR	36.01	0.24
	Other Payable	0.11	-
		42.99	**1,016.76**

Jain Mehndiratta & Associates Chartered Accountants Delhi

REBREATHE MEDICAL DEVICES INDIA PVT. LTD.

REBREATHE MEDICAL DEVICES INDIA PVT. LTD.

(₹ in Lakhs)

	Particulars	For the year ending on March 31, 2026	For the year ending on March 31, 2025
Note-16	**Revenue From Operations**		
	(A) Manufactured & Trading Sales		
	Domestic	3,162.81	9,832.57
	Export Sale	-	-
	(B) Sale of Services	-	-
	Less : Goods and Service tax	-	-
	Net gain / (loss) on settlement of commodity forward/Future contract	-	-
	Total	**3,162.81**	**9,832.57**
Note-17	**Other Income**		
	Interest Income & Others Non-operating income		
	Interest On FDR	8.56	8.33
	Other Income	-	0.33
	Total	**8.56**	**8.65**
Note-18	**Purchas eof Goods**		
	Purchase	2,447.13	9,971.42
		2,447.13	**9,971.42**
Note-19	**Changes in Inventories**		
	Closing Balance		
	Traded goods	252.74	862.79
	Total Closing balance	**252.74**	**862.79**
	Opening Balance		
	Traded goods	862.79	521.58
	Total Opening Balance	**862.79**	**521.58**
	Total	**610.05**	**(341.21)**
Note-20	**Employee Benefit Expense**		
	Salaries, wages and bonus	39.65	59.97
	Director Remuneration	-	-
	Gratuity & Leave Encashment	-	-
	Staff welfare expenses	0.18	-
	Total	**39.83**	**59.97**
Note-21	**Finance cost**		
	Bank Charges and Other Interest Charges	0.02	-
	Total	**0.02**	-

Jain Mohnot & Associates Chartered Accountants Delhi

REBREATHE MEDICAL DEVICES INDIA PVT. LTD.

REBREATHE MEDICAL DEVICES INDIA PVT. LTD.

Note-22 **Depreciation and Amortisation Expense**

Depreciation of property, plant and equipment & Impairment	4.40	0.15
Total	**4.40**	**0.15**

Note-23 **Other expenses**

Operational Expenses		
Travelling and conveyance	-	0.51
Legal and professional and consultancy charges	3.33	0.10
Rates, duties and taxes	-	0.97
Conveyance charges	-	0.05
Audit Fees	1.00	1.10
R&D Exp	0.03	-
Consultancy charges	-	3.56
Freight & labour charges	11.23	7.89
Other expenses	0.32	-
Total	**15.91**	**14.19**

Jain [illegible] & Associates Chartered Accountants Delhi

REBREATHE MEDICAL DEVICES INDIA PVT. LTD.

REBREATHE MEDICAL DEVICES INDIA PVT. LTD.

24 Other Disclosures

(Amount in Lacs)

24.1 Payment to Auditors

The company has provided the following amounts to the auditors during the year

	Current Year	Previous Year
~Audit Fees	1 00	1.10
	1.00	**1.10**

24.2 Disclosures as required under the Micro, Small and Medium Enterprises Development Act, 2006 ('MSMED Act') based on the information available with the company are given below:

Particulars	31st March 2026	31st March 2025
Principal amount due to suppliers registered under the MSMED Act and	-	-
Interest amount due to suppliers registered under the MSMED Act and	-	-
Principal amount paid to suppliers registered under the MSMED Act,	-	-
Interest paid other than under section 16 of MSMED Act to suppliers	-	-
Interest paid under section 16 of MSMED Act to suppliers registered		
Interest Due and payable towards suppliers registered under MSMED		
Further Interest remaining due and payable for earlier years	-	-

24.3 Remuneration to Directors

The company has paid as such remuneration to directors during F Y 2025-26

	31st March 2026	31st March 2025
Arun Handa	25.70	**22.11**
	25 70	22 11

24.4 Expenditure/ Income in foreign currency

The Company do not have any income or expense in foreign currency during the year or in the immediately preceding previous year.

24.5 Related Party Disclosures as per IND AS 24

A. Details of related parties:

Description of relationship	Name of related parties
(a) Key Management Personnel	
Director	Arun Handa
Director	Anupam Gupta
Director	Rajesh Mohan Rai
(b.) Associate Company	Servotech Renewable Power System Limited (earlier known as Servotech Power System Limited) Bhatia Electronics Products Private Limited

DISCLOSURE OF RELATED PARTY TRANSACTION

PARTICULARS	Associate Company	KEY MGMT. PERSONNEL	RELATIVE OF KEY MGMT.	TOTAL
Sale	**1,084.15**	-	-	**1,084.15**
Servotech Renewable Power System Ltd	973.89	-	-	973.89
Bhatia Electronics Products Private Limited	110.26			110.26
~Previous Year	-	-	-	-
Remuneration	-	**25.70**	-	**25.70**
Arun Handa	-	25.70	-	25.70
~Previous Year	-	*22.11*	-	*22.11*

24.6 Accounting of Deferred Tax as per IND AS 12

Following movements have been done in the provision of Deferred Tax

	Current Year	Previous Year
Opening Balance of Deferred Tax Asset (-)/liability(+)	-0.08	-0.09
Add/Less: Provision to be made	2 89	0.01
Closing Balance of Deferred tax Asset (-)/ Liability(+)	**2.81**	**-0.08**

24.7 Basic earning per share has been calculated by dividing profit for the year attributable to equity shareholders by the weighted average

	Current Year	Previous Year
Profit after Taxation (Rs in Lacs)	40.45	102.29
Weighted average number of shares (No.)	1.50	1.50
Earning Per Share (INR per Share)	26 96	68.19
Diluted Earning Per Share (INR per Share)	26 96	68.19

REBREATHE MEDICAL DEVICES INDIA PVT. LTD.

REBREATHE MEDICAL DEVICES INDIA PVT. LTD.

There are no dilutive instruments outstanding in F.Y 2025-26, making diluted EPS equals to the basic EPS.

24.8 Employee Benefit Expenses

Defined Contribution Plan

The provision for ESI and EPF is not applicable to the company

Retirement Benefit Plans

The provision for gratuity is not applicable to the company since all employees have tenure of below 5 years.

24.9 Creditors & Debtors are subject to confirmations

24.10 Previous year figures have been regrouped / restated where required

24.11 Other Statutory information

(i) The Company do not have any Benami property, where any proceeding has been initiated or pending against the company for holding any Benami property.

(ii) The Company do not have any transaction with companies struck off.

(iii) The Company do not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period.

(iv) The Company have not traded or invested in Crypto currency or Virtual currency during the financial year.

(v) The Company have not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (intermediaries) with the understanding that the Intermediary shall;

(a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or

(b) provide any guarantee, security or the like on behalf of the ultimate beneficiaries.

(vi) The Company have not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the compant shall:

(a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or

(b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(vii) The Company have not any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961

(viii) The Comapny has not been declared wilful defaulter by any bank and financial institution or government or any governement authority.

(ix) The Company has complied with the number of layers prescribed under clause (87) of section 2 of the act read with the companies (Restriction on number of layers) Rules, 2017.

(x) The Company has not revalued its property, plant and equipment (including right to use assets) or intangible assets or both during the current and previous year.

(xi) The title deeds of all the immovable properties (other than properties where the company is the lessee and the lease agreements are duly executed in the favour of lessee) are held in the name of the company.

24.12 The other reporting requirements of Schedule III, as applicable to Division-I companies are not applicable to the company, therefore, we have not commented on it.

For Jain Mehndiratta & Associates
[Chartered Accountants]
FRN: 018617N

Akshay Jain
[Partner]
M.No.: 543472
Place: Delhi
Date: 27/04/2026

For Rebreathe Medical Devices India Private Limited

RAJESH RAI
(DIRECTOR)
DIN 09050751

ARUN HANDA
(DIRECTOR)
DIN 09220136

REBREATHE MEDICAL DEVICES PRIVATE LIMITED
CIN : U33119DL2021PTC383180
REG. ADD. : HOUSE -49, FLOOR 1ST , PKT-1, SEC 11, ROHINI, DELHI -110085

S.No.	Ratio Analysis	Numerator	31-03-2026	31-03-2025	Denominator	31-03-2026	31-03-2025	31-03-2026	31-03-2025	% Change	Remarks
1	Current Ratio	**Current Assets**			**Current Liabilities**			**1.01**	**1.10**	9%	
		Inventories	253	863	Creditors for goods and services	1,872	163				
		Trade Receivables	1,262	427	Short term loans	-	-				
		Cash and Bank balances	109	6	Bank Overdraft						
		other Receivables/Accruals			Cash Credit						
		Loans and Advances	-	-	Outstanding Expenses						
		Disposable Investments			Provision for taxation						
		Any other current assets	318	76	Proposed dividend						
					Unclaimed Dividend						
					Any other current liabilities	56	1,082				
			1,941	**1,371**		**1,929**	**1,245**				
2	Debt Equity Ratio	**Total Liabilities** (Long Term Borrowings)	1	1	**Shareholder's Equity** (Total Shareholders Equity)	290	250	**0.00**	**0.00**	14%	
3	Debt Service Coverage Ratio	**Net Operating Income** Net Profit after tax + non-cash operating expenses like depreciation and other amortizations + Interest+other adjustments like loss on sale of fixed assets, etc.	NA	NA	**Debt Service** Current Debt Obligation (Total Finance Cost + Principal Repayment of Term Loans)	NA	NA	**NA**	**NA**	NA	NA
4	Return on Equity Ratio	**Profit for the period** Net Profit after taxes	40	102	**Avg. Shareholders Equity** (Beginning shareholders' equity + Ending shareholders' equity) ÷ 2	270	199	**0.15**	**0.51**	71%	This is due to decrease in profit during the year
5	Inventory Turnover Ratio	**Cost of Goods sold** (Opening Stock + Purchases) – Closing Stock	NA	NA	**Average Inventory** (Opening Stock + Closing Stock)/2	NA	NA	**NA**	**NA**	NA	
6	Trade Receivables Turnover Ratio	**Net Credit Sales** Credit Sales	3,162.81	9,832.57	**Average Trade Receivables** (Beginning Trade Receivables + Ending Trade Receivables) / 2	84[illegible].12	477.42	**3.75**	**21**	82%	This is due to decrease in Revenue during F.Y 2025-26
7	Trade Payables Turnover Ratio	**Total Purchases** Purchases	2,447.13	9,971.42	**Average Trade Payables** (Beginning Trade Payables + Ending Trade Payables) / 2	[illegible]7.65	5[illegible]7.15	**2.40**	**17.28**	86%	This is due to decrease in Purchase during F.Y 2025-26

8	**Net Capital Turnover Ratio**	**Net Sales** Total Sales - Sales Return	3,162.81	9,832.57	**Average Working Capital** Current Assets - Current Liabilities	13	126	**248.83**	**77.82**	220%	This is due to decrease in Revenue during F.Y 2025-26.
9	**Net Profit Ratio**	**Net Profit** Profit After Tax	40	102	**Net Sales** Sales	3,163	9,833	**0.01**	**0.01**	23%	This is due to decrease in profit during F.Y 2025-26.
10	**Return on Capital employed**	**EBIT** Profit before Interest and Taxes	54	137	**Capital Employed** (Equity + Long Term Debt)	292	251	**0.19**	**0.54**	66%	This is due to decrease in profit during F.Y 2025-26.
11	**Return on Investment**	**Return/Profit/Earnings** (Profit After Tax)	40	102	**Investment** (Average of Capital Employed)	271	199	**0.15**	**0.51**	71%	This is due to decrease in Profit during F.Y 2025-26.

For Jain Mehndiratta & Associates
[Chartered Accountants]
FRN: 018617N

Akshay Jain
[Partner]
M.No.: 543472
Place: Delhi
Date: 27/04/2026

For Rebreathe Medical Devices India Private Limited

RAJESH RAI (DIRECTOR) DIN 05050751

ARUN HANDA (DIRECTOR) DIN 09226135

REBREATHE MEDICAL DEVICES PRIVATE LIMITED
CIN : U33119DL2021PTC383180
REG. ADD. : HOUSE -49, FLOOR 1ST , PKT-1, SEC 11, ROHINI, DELHI -110085
Period : 1st April 25 to 31st March, 2026

ANNEXURE :" DEPRECIATION ALLOWABLE UNDER SECTION 32 OF INCOME TAX ACT,1961"
FOR THE PERIOD ENDED ON 31st March, 2026

S no.	NAME OF THE ASSETS	RATE OF DEP.	W.D.V. AS ON 01.04.25	ADDITIONS		SALE DURING THE YEAR	TOTAL	DEP. FOR THE YEAR	W.D.V. AS ON 31.12.2026
				BEFORE 03.10.25	On or AFTER 03.10.25				
1	Mobile	40%	16,639	-	-	-	16,639	6,656	9,984
2	Furniture	10%	33,270	-	-	-	33,270	3,327	29,943
3	Plant & Machinery	15%	27,358	-	285,47,912	-	285,75,270	21,45,197.15	264,30,073
	Total		**77,267**	**-**	**285,47,912**	**-**	**286,25,179**	**21,55,180**	**264,69,999**

REBREATHE MEDICAL DEVICES PRIVATE LIMITED
CIN : U33119DL2021PTC383180
REG. ADD. : HOUSE -49, FLOOR 1ST , PKT-1, SEC 11, ROHINI, DELHI -110085

Annexure B: Creditors Ageing

(₹ in Lakhs)

Trade Payables ageing schedule: As at 31st March 2026

Particulars	Outstanding for following periods from due date of payment				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) MSME					-
(ii) Others	1270.20	588.06	14.05	0	1,872.32
(Iii) Disputed Dues- Msme					-
(Iv) Disputed Dues - Others					-

Trade Payables ageing schedule: As at 31st March 2025

Particulars	Outstanding for following periods from due date of payment				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) MSME	-	-	-	-	-
(ii) Others	150.67	-	12.31	-	162.98
(Iii) Disputed Dues- Msme	-	-	-	-	-
(Iv) Disputed Dues - Others	-	-	-	-	-

REBREATHE MEDICAL DEVICES INDIA PVT. LTD.

REBREATHE MEDICAL DEVICES INDIA PVT. LTD.

REBREATHE MEDICAL DEVICES PRIVATE LIMITED
CIN : U33119DL2021PTC383180
REG. ADD. : HOUSE -49, FLOOR 1ST , PKT-1, SEC 11, ROHINI, DELHI -110085

Annexure A: Debtors Ageing **(₹ in Lakhs)**

Particulars	Outstanding for following periods from due date of payment (as at March 31, 2026)					
	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	Total
Undisputed Trade receivables – considered good	1,045.56	100.33	83.64	1.69	30.32	1,261.53
Undisputed Trade Receivables – which have significant increase in credit risk						
Undisputed Trade Receivables – credit impaired						
Disputed Trade Receivables– considered good						
Disputed Trade Receivables – which have significant increase in credit risk						
Disputed Trade Receivables – credit impaired						
Total	**1,045.56**	**100.33**	**83.64**	**1.69**	**30.32**	**1,261.53**

Particulars	Outstanding for following periods from due date of payment (as at March 31, 2025)					
	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	Total
Undisputed Trade receivables – considered good	340.29	83.75	1.69	-	1.00	426.72
Undisputed Trade Receivables – which have significant increase in credit risk						
Undisputed Trade Receivables – credit impaired						
Disputed Trade Receivables– considered good						
Disputed Trade Receivables – which have significant increase in credit risk						
Disputed Trade Receivables – credit impaired						
Total	**340.29**	**83.75**	**1.69**	**-**	**1.00**	**426.72**